In December of 2017, Philadelphia-based Spark Therapeutics Inc. obtained the first FDA approval of LUXTURNATM for gene therapy to treat retinal dystrophy due to a mutation in the retinoid isomerohydrolase made from the RPE65 gene (Dias et al., 2018). Here, RPE65 is linked to inherited retinal dystrophy.